The global non-invasive prenatal testing market is anticipated to reach USD 5.5 billion by 2025. Evolution of prenatal testing in the form of noninvasive tests that can serve as an intermediate step between serum screening and invasive diagnostic testing to determine the likelihood of fetal abnormality is expected to drive growth in the reproductive genetics industry over the forecast period.
In addition, presence of payers such as Anthem and Blue Shield of California that have endorsed cfDNA-based Noninvasive Prenatal Testing (NIPT) for trisomies 13, 18, and 21 is expected to impact the adoption rate of these tests, thereby resulting in increased revenue generation.
However, the projected NIPT-related price erosion in this market is expected to continue, thus intensifying competition amongst the operating participants, but restraining revenue generation to a certain extent.
Rising awareness pertaining to the prevention and screening of chromosomal anomalies, such as Down Syndrome is another factor anticipated to impact adoption. Asia Pacific is expected to register fastest year-on-year progress owing to the gradually increasing average maternal age, & increasing incidence of chromosomal aneuploidies.
- Natera Inc.
- Illumina Inc.
- Sequenom Laboratories
- Laboratory Corporation of America Holdings
- Quest Diagnostics
- F. Hoffmann-La Roche Ltd
- BGI Diagnosis
- LifeCodexx AG
- Berry Genomics Co. Ltd.
Key Topics Covered:
1 Research Methodology
2 Executive Summary
3 NIPT Market Variables, Trends & Scope
4 NIPT Market: Gestation Duration Estimates & Trend Analysis
5 NIPT Market: Risk Type Estimates & Trend Analysis
6 NIPT Market: Regional Estimates & Trend Analysis, by Gestation Period & Risk Type
7 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/7978c2/noninvasive
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---non-invasive-prenatal-testing-market-to-reach-55-billion-by-2025-with-natera-illumina--quest-diagnostics-dominating-300382050.html
SOURCE Research and Markets